|Articles|April 10, 2020
Advances in Tardive Dyskinesia: A Review of Recent Literature
Advertisement
In the past three years, the U.S. Food and Drug Administration has approved two medications for tardive dyskinesia, contributing to a resurgent interest in recognition, management, and treatment.
This Psychiatric Times® supplement provides a brief review of primarily recent literature on tardive dyskinesia, including signs and symptoms, risk factors and epidemiology, potential mechanisms, and screening and treatment.
Newsletter
Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Psychiatric Times
1
Closing the Gap in Schizophrenia Care: Insights From the INTEGRATE Guidelines
2
Preliminary Report on Dangers of AI Chatbots
3
The Trial of ChatGPT: What Psychiatrists Need to Know About AI, Suicide, and the Law
4
Fostering Resiliency in Mental Health Professionals: A Strengths-Based, Trauma-Informed Framework
5